Company delivers steady performance and achieves key milestones across critical care, pediatrics, and hospital-based outpatient therapy MINNEAPOLIS, MN, Nov. 12, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, addressing the critical interplay between the heart and kidneys, today reported financial results for the third quarter ended September 30, 2025 and provided a business update on recent milestones advancing the company’s cardiorenal growth strategy. Third Quarter 2025 HighlightsTotal revenue of $2.2 million, down 6% year-over-year and up 29% sequentially, reflecting increased consumable utilization and stronger U.S. console sales on a sequential quarter basis. On a pro-forma basis, revenue grew approximately 7%...

Gross Profit Increases 180% to $6.7 Million Revenue for the First Nine Months of 2025 Increases 326% to $36.5 Million, a $27.9 Million Increase over the Prior Year Generated $3.0 Million in Positive Cash Flow from Continuing Operations in the First Nine Months of 2025 Reaffirms 2025 Guidance for Net Income of ~$1.3 Million on Revenue of Over $45 Million; Projects 2026 Income from Operations of ~$12.0 Million on Revenue of More than $50 Million Conference Call to be Held Today at 8:30 am EST NEW YORK, NY , Nov. 12, 2025 (GLOBE NEWSWIRE) — 1847 Holdings LLC (“1847” or the “Company”) (“1847” or the “Company”) (OTCID: LBRA), a holding company specializing in identifying overlooked, deep-value investment opportunities in middle-market businesses, today announced financial results for...

 – Quarterly performance characterized by higher revenues, reduced cost structure and improved bottom line – – Successful business integration drives 10.9% sequential quarter-over-quarter EEG/ERP scan volumes and 30% sequential revenue growth – KENMORE, N.Y., Nov. 12, 2025 (GLOBE NEWSWIRE) — Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today reported financial results for the three and nine months ended September 30, 2025. Business HighlightsThird quarter 2025 revenue grew more than tenfold year-over-year and 30% sequentially quarter-over-quarter, demonstrating both the immediate benefits from Firefly’s May 2025 acquisition of Evoke Neuroscience, Inc. (“Evoke”)...

Quarter marked continued platform expansion, AI integration, and operational progress across reAlpha’s real estate and mortgage businesses DUBLIN, Ohio, Nov. 12, 2025 (GLOBE NEWSWIRE) — reAlpha Tech Corp. (Nasdaq: AIRE) (the “Company” or “reAlpha”), an AI-powered real estate technology company, today announced financial results for the quarter ended September 30, 2025. Financial HighlightsRevenue increased 326% to $1,445,137 in the third quarter of 2025, compared to $339,227 in the third quarter of 2024. Cash was approximately $9.3 million as of the end of the third quarter of 2025, compared to $7.0 million as of the end of the third quarter of 2024. Gross profit was $749,580 in the third quarter of 2025, compared to $225,866 in the third quarter of 2024. The increase was primarily driven by an increase in mortgage brokerage...

Third quarter 2025 GAAP net loss of $(12.5) million or $(0.57) per basic weighted average common share and  Distributable Earnings(1) of $3.5 million or $0.16 per basic weighted average common share AFC shareholders approve conversion from mortgage REIT to BDC WEST PALM BEACH, Fla., Nov. 12, 2025 (GLOBE NEWSWIRE) — Advanced Flower Capital Inc. (Nasdaq: AFCG) (“Advanced Flower Capital,” “AFC,” or the “Company”) today announced its results for the quarter ended September 30, 2025. AFC reported generally accepted accounting principles (“GAAP”) net loss of $(12.5) million or $(0.57) per basic weighted average common share and Distributable Earnings of $3.5 million or $0.16 per basic weighted average common share for the third quarter of 2025. “We continue to make progress resolving our nonaccrual positions and driving loan repayments...

‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) — CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its business. Recent Corporate Highlights:CorMedix announces $104.3 million of net revenue and $130.8 million of pro forma net revenue(1) for the third quarter of 2025, largely driven by higher than...

Business development: Secures royalty economic interests in two early stage partnered assets through XOMA Royalty’s announced expected acquisition of LAVA Therapeutics. Company acquisitions: •Completed XOMA Royalty’s acquisitions of Turnstone Biologics and HilleVax; • announced acquisitions of LAVA Therapeutics and Mural Oncology; • acted as structuring agent for XenoTherapeutics’ acquisition of ESSA Pharma. Key Pipeline advancements: • Zevra Therapeutics submitted a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) seeking marketing approval for arimoclomol as a treatment for Niemann-Pick Type C; • Rezolute Bio reconfirmed its expectations to announce topline data in December from its Phase 3 ersodetug trial in patients with congenital hyperinsulinism (HI) and announced alignment with FDA on streamlined...

Transformational Acquisition Sets Stage for Strong Growth Going Forward LOUISVILLE, Ky., Nov. 12, 2025 (GLOBE NEWSWIRE) — Creative Realities, Inc. (“Creative Realities,” “CRI,” or the “Company”) (NASDAQ: CREX), a leading provider of digital signage, media and AdTech solutions, today announced its financial results for the fiscal third quarter ended September 30, 2025. Highlights:Third quarter revenue of $10.5 million versus $14.4 million in the prior-year period Gross profit of $4.8 million for the three months ended September 30, 2025 versus $6.6 million in the third quarter of fiscal 2024 Net loss of $7.8 million for the third quarter of 2025 versus net income of $0.1 million for the prior period Adjusted EBITDA* of $0.8 million for the third quarter of 2025 versus $2.3 million in the prior-year period Annual recurring revenue...

Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 2025. Recent Corporate Highlights:Regulatory Pathway Advancement: The Company continues to make progress in its regulatory...

Announces CEO Transition SHOEMAKERSVILLE, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) — Hydrofarm Holdings Group, Inc. (“Hydrofarm” or the “Company”) (Nasdaq: HYFM), a leading independent manufacturer and distributor of branded hydroponics equipment and supplies for controlled environment agriculture, today announced financial results for its third quarter ended September 30, 2025. Comparison of Third Quarter vs. Prior Year Period:Net sales decreased to $29.4 million compared to $44.0 million. Gross Profit Margin decreased to 11.6% of net sales compared to 19.4%. Adjusted Gross Profit Margin(1) decreased to 18.8% of net sales compared to 24.3%. SG&A expense and Adjusted SG&A(1) expense decreased by 6.8% and 7.4%, respectively. Net loss increased to $16.4 million compared to $13.1 million. Adjusted EBITDA(1) of $(4.4) million...